Thursday, November 12, 2026
Tag
Medicare, MolDX, and other coverage decisions for MRD testing.
The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera for progression, recurrence, or relapse testing in muscle-invasive bladder cancer.
CMS MolDX
The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera among the assays covered for progression, recurrence, or relapse testing in ovarian cancer.
CMS MolDX
The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera for neoadjuvant breast cancer and lists NeXT Personal, Pathlight, RaDaR, and Signatera for recurrence or relapse testing in advanced breast cancer.
CMS MolDX
The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera for the diagnosis of recurrence or relapse in patients with a personal history of non-small cell lung cancer.
CMS MolDX
The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera, Guardant Reveal, and Oncodetect for the diagnosis of progression, recurrence, or relapse in advanced colorectal cancer.
CMS MolDX
The MolDX billing article A58434, in the revision effective January 1, 2026, lists HPV-negative head and neck squamous cell carcinoma among covered indications for recurrence testing with RaDaR, and lists HPV-driven oropharyngeal squamous cell cancer among covered indications for NavDx.
CMS MolDX
The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera for monitoring response to immune-checkpoint inhibitor therapy in advanced solid tumors and Guardant Response for inoperable or metastatic solid tumors.
CMS MolDX